Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort

Tarih
2021
Yazar
KÖMÜR, SÜHEYLA
Karasahin, Omer
Kalkan, Irem Akdemir
Dal, Tuba
ALTUNIŞIK TOPLU, SİBEL
Harputoglu, Murat
Sarigul, Figen
Mete, Ayse Ozlem
Yildiz, Yesim
Esmer, Fatih
Kandemir, Ozlem
NAZİK, SELÇUK
İNAN, DİLARA
Akgul, Fethiye
Kaya, Safak
Tunc, Nurettin
BALIN, ŞAFAK ÖZER
BAYINDIR, YAŞAR
TAŞOVA, YEŞİM
Akar, Fesih
Oren, Meryem Merve
Ayhan, Merve
Demir, Yakup
ÇELEN, MUSTAFA KEMAL
Üst veri
Tüm öğe kaydını göster
Özet
Background: Chronic hepatitis B (CHB) is a viral infection that can result in life-threatening conditions, such as hepatocellular carcinoma and cirrhosis. Tenofovir, which is used for the treatment of CHB, is a nucleotide analog that inhibits HBV-DNApolymerase and has two formulations: disoproxil and alafenamide. In contrast to tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF) penetrates the whole hepatocyte without being eliminated due to its longer plasma half-life and greater plasma stability. As a result, side effects such as proximal renal tubulopathy and loss of bone density are less common in the treatment of TAF and have similar efficacy to TDF.
Bağlantı
http://hdl.handle.net/20.500.12627/171064
https://doi.org/10.5812/hepatmon.104943
Koleksiyonlar